Intra-Cellular Therapies (ITCI) PT Raised to $71 at Goldman Sachs
Goldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $71.00 (from $64.00) while maintaining a Buy rating.
Goldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $71.00 (from $64.00) while maintaining a Buy rating.